RE:RE:New September company presentation Now for the real facts ... Demand is hot for big results in key markets like mBC with an unmet treatment need. As for Big Pharma, the emphasis now is on finding therapies that have been de-risked with human data, as ONCY has been demonstrating over time, and as had been accomplished and reported on today in HR+/HER2- Breast Cancer.
Analysis shows that around 122,000 HR+/HER2- mBC patients will be ready for pelareorep + paclitaxel treatment in the combined United States and EU-27 global regions.
Using the modeling that Kirk Look referenced in the Cantor chat and translating that into the above 122,000 mBC patients, peak pelareorep annual sales would reach approximately US$5.89 Billion in HR+/HER2- mBC alone.